Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Código da empresaBBNX
Nome da EmpresaBeta Bionics Inc
Data de listagemJan 30, 2025
CEOMr. Sean Saint
Número de funcionários291
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 30
Endereço11 Hughes
CidadeIRVINE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92618
Telefone19494277785
Sitehttps://www.betabionics.com
Código da empresaBBNX
Data de listagemJan 30, 2025
CEOMr. Sean Saint
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados